Early Sodium-Glucose Cotransporter-2 Inhibitor Use After Acute Kidney Injury in Type 2 Diabetes

In adults with type 2 diabetes recovering from AKI-D, SGLT-2 inhibitor prescription within 30 days after discharge was associated with fewer adverse kidney events than prescription at 31 to 90 days, without significant differences in mortality, cardiovascular events, or recorded short-term safety outcomes. These findings support timely initiation of SGLT-2 inhibitors during the post-AKI recovery period and provide a rationale for prospective randomized clinical trials.

Corresponding Author: Vin-Cent Wu, PhD, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan S Rd, B4, Clinical Research Bldg, Room 1555, Taipei 100, Taiwan (q91421028@ntu.edu.tw).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.